Vantia Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Liquidation

Vantia Therapeutics General Information

Description

Developer of novel small molecule drugs designed to address underserved medical markets. The company's drugs directly target the causes of nocturia that causes sufferers to wake frequently during the night in order to urinate, enabling patients to get the required treatment in the areas of urology and problems concerning their health.

Contact Information

Website
www.vantia.com
Formerly Known As
Newincco 775 Limited
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Epsilon House Enterprise Road
  • Southampton Science Park
  • Southampton SO16 7NS
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Epsilon House Enterprise Road
  • Southampton Science Park
  • Southampton SO16 7NS
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vantia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Bankruptcy: Liquidation 09-Feb-2021 Completed Out of Business
6. Later Stage VC (Series A) 12-Jun-2018 Completed Generating Revenue
5. Later Stage VC 18-Mar-2016 Completed Generating Revenue
4. Secondary Transaction - Private Completed Generating Revenue
3. Early Stage VC (Series B) 30-Sep-2012 Completed Generating Revenue
2. Early Stage VC (Series B) 06-Jul-2011 $6.46M $44.4M Completed Generating Revenue
1. Early Stage VC (Series A) 24-Mar-2008 $38M $38M Completed Startup
To view Vantia Therapeutics’s complete valuation and funding history, request access »

Vantia Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B NV
Series B
Series A 23,066,001 $0.014178 $1.42 $1.42 1x $1.42 3.09%
To view Vantia Therapeutics’s complete cap table history, request access »

Vantia Therapeutics Patents

  • 117

    Total Documents Applications and Grants

  • Total Patents Families

  • 35

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Vantia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201105537-D0 New process Inactive 31-Mar-2011
EP-2691390-A1 Process for the preparation of 1 - ( 2 -methyl - 4 - ( 2, 3, 4, 5 - tetrahydro - 1 - benzazepin- 1 -ylcarbonyl) benzylcarbamoyl) - l - proline - n, n- dimethylamide Active 31-Mar-2011
EP-2691390-B1 Process for the preparation of 1 - ( 2 -methyl - 4 - ( 2, 3, 4, 5 - tetrahydro - 1 - benzazepin- 1 -ylcarbonyl) benzylcarbamoyl) - l - proline - n, n- dimethylamide Inactive 31-Mar-2011
WO-2012131389-A1 Process for the preparation of 1 - ( 2 -methyl - 4 - ( 2, 3, 4, 5 - tetrahydro - 1 - benzazepin- 1 -ylcarbonyl) benzylcarbamoyl) - l - proline - n, n- dimethylamide Inactive 31-Mar-2011
US-20140066619-A1 Process for the preparation of 1 - (2-methyl-4- (2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl) benzylcarbamoyl) - l - proline - n, n-dimethylamide Active 31-Mar-2011 C07D403/12
To view Vantia Therapeutics’s complete patent history, request access »

Vantia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vantia Therapeutics Investments (1)

Vantia Therapeutics’s most recent deal was a Corporate Asset Purchase with Vantia Therapeutics (Phi House in Southampton, United Kingdom). The deal was made on 01-Aug-2012.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vantia Therapeutics (Phi House in Southampton, United Kingdom) 01-Aug-2012 Corporate Asset Purchase Buildings and Property
To view Vantia Therapeutics’s complete investments history, request access »

Ready to get started?

Request a free trial

Vantia Therapeutics FAQs

  • When was Vantia Therapeutics founded?

    Vantia Therapeutics was founded in 2007.

  • Where is Vantia Therapeutics headquartered?

    Vantia Therapeutics is headquartered in Southampton, United Kingdom.

  • What is the size of Vantia Therapeutics?

    Vantia Therapeutics has 3 total employees.

  • What industry is Vantia Therapeutics in?

    Vantia Therapeutics’s primary industry is Drug Discovery.

  • Is Vantia Therapeutics a private or public company?

    Vantia Therapeutics is a Private company.

  • What is Vantia Therapeutics’s current revenue?

    The current revenue for Vantia Therapeutics is .

  • How much funding has Vantia Therapeutics raised over time?

    Vantia Therapeutics has raised $72.6M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process